Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 6/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3493475 | 1.00 | GPR119 (0.47) | GPR119KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL471550 | 0.86 | KMT2A (0.46) | GPR119KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16496996 | 0.85 | IDO1 (0.46) | GPR119KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3814131 | 0.85 | IDO1 (0.46) | GPR119KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL13636573 | 0.85 | GPR119 (0.45) | GPR119KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1589943 | 0.85 | SCD (0.45) | GPR119KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL3814137 | 0.85 | IDO1 (0.46) | GPR119KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12265488 | 0.85 | KDM4E (0.45) | GPR119KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL29624718 | 0.85 | IDO1 (0.46) | GPR119KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1589942 | 0.85 | SCD (0.45) | GPR119KDM4EALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | GPR119 25/4885KDM4E 1143/4885ALDH1A1 503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.